ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat ImmunoInflammatory Diseases of Unmet Need, to Combine in All-Stock Merger Under the terms of the merger agreement, which has been unanimously approved by the boards of directors of both companies, existing ReShape stockholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape's actual net cash at closing compared to a target net cash ...

Exhibit 99.1 ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update Revenue totaled $1.9 million for the three months ended March 31, 2024, which represents a contraction of 15.0%, or $0.3 million compared to the same period in 2023. The primary reason is due to a decrease in sales volume primarily due to GLP-1 pharmaceuticals. Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% ...

ReShape Lifesciences, Inc. (NASDAQ:RSLS) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relatons Paul Hickey - President, CEO & Director Thomas Stankovich - CFO Conference Call Participants Operator Good afternoon, and thank you for joining the ReShape Lifesciences First Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications. Michael Miller Good afternoon, and thank you for joining the first quarter 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) | | | For the fiscal year ended December 31, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or other jurisdiction of incorporation or organization) (IRS Employer Identificatio ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President & Chief Executive Officer Caroline Apovian - Member-ReShape Scientific Advisory Tom Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group. Operator Good afternoon and thanks for joining the ReShape Lifesciences Third Quarter 2023 Conference Call. I would now like to turn the call over to ...

Financial Performance - Revenue for Q3 2023 was $2.155 million, a decrease of 23.0% compared to $2.798 million in Q3 2022[101] - Gross profit for Q3 2023 was $1.288 million, representing 59.8% of total revenue, down from 75.1% in Q3 2022[104] - Operating loss for Q3 2023 was $3.880 million, compared to an operating loss of $12.301 million in Q3 2022[94] - Total operating expenses for Q3 2023 were $5.168 million, significantly higher than $2.605 million in Q3 2022, reflecting a 239.9% increase[94] - The company recorded a net loss of $3.534 million in Q3 2023, compared to a net loss of $12.186 million in Q3 2022[94] - Total revenue for the nine months ended September 30, 2023, was $6.7 million, a decrease of 17.6% or $1.4 million compared to $8.1 million in the same period in 2022[108] - The company reported a net loss of $8.9 million for the nine months ended September 30, 2023[119] Expenses and Cost Management - Research and development expenses for Q3 2023 were $542 thousand, accounting for 25.2% of revenue[94] - Sales and marketing expenses for the nine months ended September 30, 2023, decreased by $5.8 million, or 48.5%, to approximately $6.1 million, compared to $11.9 million for the same period in 2022[112] - General and administrative expenses for the nine months ended September 30, 2023, decreased by $4.3 million, or 33.1%, to approximately $8.7 million, compared to $13.0 million for the same period in 2022[113] - Operating expenses for the nine months ended September 30, 2023, totaled $17.2 million, a decrease of 50.7% or $17.7 million from $34.9 million in the same period in 2022[112] - The Company is managing growth of expenditures based on available cash flows, which may include reducing marketing and development costs[125] Future Outlook and Strategy - The company anticipates FDA approval for the LAP-BAND 2.0 in early 2024, which is expected to boost sales[101] - The company is focusing on a targeted digital media campaign to increase demand for the Lap-Band system[101] - The Company aims to increase brand recognition and patient demand through focused marketing efforts[125] - Plans include growing sales of the Lap-Band product line domestically and internationally, and introducing ReShapeCare and ReShape Marketplace[125] - The Company is focusing on a metrics-driven approach through a sustainable and scalable business model via a digital lead generation strategy[117] - The Company anticipates FDA approval for Lap-Band 2.0 before the end of fiscal year 2023[127] - Future capital requirements are uncertain and depend on various factors including market acceptance and costs associated with clinical supplies[126] - The Company is exploring synergistic opportunities to expand its portfolio in minimally invasive treatments for obesity[125] Operational Changes - The company has relocated its principal executive offices to a new facility in Irvine, California, with a lease term of 36 months[92] - As of September 30, 2023, the company had net working capital of approximately $2.9 million, primarily due to cash and cash equivalents of $1.5 million[117] - Net cash used in operating activities for the nine months ended September 30, 2023, was $14.5 million, compared to $19.1 million for the same period in 2022[119] Risks and Challenges - The Company does not currently generate sufficient revenue to cover operating costs and expects this trend to continue due to a modified strategy[125] - The Company faces risks related to the development of medical devices, impacting capital outlays and operating expenditures[126] - There have been no material changes to significant accounting policies during the nine months ended September 30, 2023[130]

TABLE OF CONTENTS bAs filed with the U.S. Securities and Exchange Commission on September 27, 2023 Registration Statement No. 333-274227 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3841 (Primary Standard Industrial Classification Code Number) (I.R ...

TABLE OF CONTENTS bAs filed with the U.S. Securities and Exchange Commission on September 11, 2023 Registration Statement No. 333-274227 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RESHAPE LIFESCIENCES INC. Delaware (State or other jurisdiction of incorporation or organization) (Exact name of registrant as specified in its charter) 3841 (Primary Standard Industrial Classification Code Number) (I.R ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on August 25, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3841 (Primary Standard Industrial Classification Code Number) 26-1828101 (I.R.S. Employer Ident ...